Key result
New oral anticoagulant drugs for thromboprophylaxis require improved phase II trial methodologies to optimize clinical development.
Suboptimal phase II designs may hinder NOAC thromboprophylaxis development; leaves open refined dose-finding and endpoints to guide phase III.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Samama et al. (2010) studied this question. New oral anticoagulant drugs for thromboprophylaxis require improved phase II trial methodologies to optimize clinical development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: